Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $14.0052W HIGH $37.77
Volume
136.72 K
Value Traded
18.42 M
Short % Float
12.98%
-0.13%Week
+0.54%1 Month
-22.73%3 Month
-7.43%6 Month
-54.65%5 Year
+140.58%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
508.32 M
EPS (TTM)
1.10
P/E Ratio
20.44
Ent. Value
438.46 M
Total Shares
22.65 M
Float Shares
21.68 M
Insiders
4.29%
Institutions
103.20%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TCMD Catalyst Timeline
Dated clinical, regulatory and corporate events for Tactile Systems Technology, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tactile Systems Technology, Inc.
113Total events
0Upcoming
6Tier-1 (high impact)
2016 to 2026Coverage
Event history 50
▲Timing GuidancePresentation
FY 2025 goals: $350M+ revenue, $50M+ adj. EBITDA, $75M+ cumulative free cash flow
▲Quarterly UpdateCorporate
Updated 2025 Financial Outlook: Revenue $317M-$321M, Adjusted EBITDA $38M-$39.5M
●Oral PresentationPresentation
Presented new clinical data from head and neck lymphedema trial
head and neck lymphedemasource ↗
▼Quarterly UpdateCorporate
Updated 2025 financial outlook: revenue $309M-$315M, adjusted EBITDA $32M-$34M
▲Product LaunchNimblPost-Market
Launched Nimbl for lower extremity lymphedema
lower extremity lymphedemasource ↗
●Equity OfferingCorporate
Share repurchase program effective October 30, 2024, expires October 31, 2026
◆IP Litigation RulingIP / Competition
Settlement hearing for derivative action Weaver v. Moen
▼Equity OfferingCorporate
Closed underwritten public offering of 2,875,000 shares at $13.00 per share
▲Enrollment CompleteTrial
Complete enrollment of Head & Neck RCT
Head and Neck-related lymphedemasource ↗
Past FDA Catalysts and PDUFA Decisions
How TCMD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D21 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 93%
Micro Cap(rank 614 of 660)
Percentile Rank
Tactile Systems Technology, Inc. faces pipeline headwinds (21/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every TCMD program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Dodd Sheri LouiseDirector, Officer (Chief Executive Officer) | Sell | -10,978 232,907 held | $29.44 | 08/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TCMD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0 % (-100 %) | 747.00 K | 62.64 K | -93.06% ( -840.45 K) |
TCMD Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TCMD ranks across every disease it competes in
Competitive Position is a premium feature
See how TCMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTCMD News
TCMDTactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results MINNEAPOLIS, MN, May 4th, 2026 - Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (Nasdaq: TCMD), a medical technology comp
Tactile Systems Technology, Inc. reported a strong performance for the first quarter of 2026, showing a 23% increase in revenue compared to the previous year. The company's CEO highlighted broad-based performance and operational agility in response to regulatory changes, along with a positive adjusted EBITDA of $3.7 million. Despite the revenue growth, operating expenses increased significantly, leading to an operating loss of $1.5 million. Overall, the company adjusted its financial outlook for 2026, expecting continued growth.
Read more →TCMDTactile Medical Strengthens Board of Directors with Appointment of Andrea Pearson
Tactile Medical has announced the appointment of Andrea Pearson to its Board of Directors effective March 9, 2026. Pearson, a seasoned executive with over 25 years of experience in healthcare, will also join the Compliance & Reimbursement and Nominating & Corporate Governance Committees. Her background includes significant roles in scaling organizations and developing growth strategies, which Tactile Medical hopes will enhance its leadership in treating chronic disorders.
Read more →TCMD▲ +6%on this news· ran to +25% by day 1
Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
Tactile Systems Technology, Inc. has reported strong financial results for the fourth quarter and full year of 2025, showcasing a 21% increase in revenue compared to Q4 2024. The company noted significant growth in sales from both its lymphedema and airway clearance product lines. Looking forward, management anticipates continued revenue growth and operational momentum entering 2026. Despite increased operating expenses and tax liabilities, the overall financial outlook remains optimistic as the company aims to strengthen its market position.
Read more →TCMDTactile Systems Technology, Inc. Reports Third Quarter 2025 Financial Results MINNEAPOLIS, MN
Tactile Systems Technology, Inc. (TCMD) reported strong financial results for the third quarter of 2025, with total revenue increasing by 17% to $85.8 million compared to the same quarter last year. The rise in revenue was driven by higher sales in both its lymphedema and airway clearance product lines. Additionally, the company announced the approval of a $25 million share repurchase program and provided an optimistic update on its financial outlook, projecting total revenue between $317 million and $321 million for the full year 2025. Overall, the company showed significant improvement in net income, reaching $8.2 million for Q3 2025.
Read more →TCMDTactile Systems Technology, Inc. Reports Second Quarter 2025 Financial Results MINNEAPOLIS, MN
Tactile Systems Technology, Inc. reported a strong financial performance for Q2 2025, with total revenue increasing by approximately 8% year-over-year, reaching $78.9 million. The company attributed this growth to significant increases in the airway clearance product line, particularly AffloVest placements. Despite overall revenue growth, operating expenses rose sharply by 13%, leading to a decrease in net income compared to the same quarter last year. Moving forward, the company remains optimistic about its strategic priorities aimed at expanding treatment options and improving patient care in the coming years.
Read more →TCMDTactile Systems Technology, Inc. Reports First Quarter 2025 Financial Results MINNEAPOLIS, MN
Tactile Systems Technology, Inc. reported a slight revenue increase of 0.3% in Q1 2025, totaling $61.3 million. The company faced challenges with a decrease in lymphedema product sales and reported an operating loss of $4.5 million. Adjusted EBITDA converted to a loss of $0.3 million, down from a profit of $1.0 million in the same quarter last year. The firm revised its 2025 financial outlook, now forecasting total revenue growth of 5-8%, a decrease from earlier estimates.
Read more →TCMDTactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
Tactile Systems Technology, Inc. reported strong financial results for the fourth quarter and full year of 2024, highlighting a successful launch of its next-generation lymphedema platform and a 10% increase in fourth-quarter revenue. The company experienced significant growth in both sales and profitability, with net income for Q4 reaching $9.7 million. However, operating expenses also rose, which could pose challenges ahead. Looking forward, Tactile Systems has set a positive revenue growth outlook for 2025, expecting total revenue to range between $316 million to $322 million.
Read more →TCMDTactile Medical Appoints Laura King to Board of Directors
Tactile Medical has appointed Laura King to its Board of Directors and various committees, effective January 13, 2025. King brings over 22 years of healthcare experience, including leadership roles at General Electric and her current position as CEO of BiaCure, Inc. The company expressed optimism about her contributions to improving patient care and expanding their impact in chronic condition therapies. Tactile Medical is known for developing at-home therapies for conditions like lymphedema and chronic pulmonary disease.
Read more →TCMDTactile Systems Technology, Inc. Reports Third Quarter 2024 Financial Results Authorizes Share Repurchase Program MINNEAPOLIS, MN
Tactile Systems Technology, Inc. (TCMD) reported its financial results for Q3 2024, showcasing a 5% increase in total revenue compared to Q3 2023, driven primarily by growth in lymphedema and airway clearance product sales. The company announced a share repurchase program of up to $30 million, reflecting confidence in its operational strategy and cash flow generation. Despite strong performance indicators, the company faced challenges due to Medicare policy changes affecting revenue.
Read more →TCMD▼ -5.9%on this news
Tactile Systems Technology, Inc. Reports Second Quarter 2024 Financial Results MINNEAPOLIS, MN
Tactile Systems Technology, Inc. reported a 7% increase in total revenue for Q2 2024, driven mainly by a strong performance in its lymphedema product line. The company achieved significant improvements in profitability, with adjusted EBITDA up 49% year-over-year. Despite strong financial results, Tactile Medical revised its revenue guidance for 2024 downwards, now expecting growth of 7% to 9%. Additionally, the company faced a slight decline in sales from the airway clearance product line, raising some concerns about long-term performance.
Read more →TCMDUNITED STATES DISTRICT COURT DISTRICT OF DELAWARE JACK WEAVER, Derivatively on Behalf of TACTILE SYSTEMS TECHNOLOGY, INC., Plaintiff, v. BRENT MOEN, et al., Defendants, -and- TACTILE SYSTEMS TECHNOLOGY, INC., Nominal Def
Tactile Systems Technology, Inc. is involved in a proposed settlement regarding a shareholder derivative action, Weaver v. Moen. The settlement, which is awaiting court approval, aims to address claims against certain current and former officers and directors of the company. A Settlement Hearing is scheduled for August 28, 2024, where the court will determine whether to approve the terms of the settlement, which includes enhanced corporate governance provisions. The settlement seeks to resolve issues raised in previous securities fraud lawsuits and aims to benefit both the company and its shareholders.
Read more →TCMDTactile Systems Technology, Inc. Reports First Quarter 2024 Financial Results Reaffirms Full Year 2024 Outlook MINNEAPOLIS, MN
Tactile Systems Technology, Inc. reported its first quarter 2024 financial results, showing a total revenue increase to $61.1 million, up from $58.8 million in Q1 2023. Lymphedema product sales grew by 5%, while airway clearance product sales saw a decrease of 4%. The company reaffirmed its full-year revenue outlook of $300 million to $305 million, representing a growth rate of approximately 9% to 11%. Despite an operating loss of $3.0 million for the quarter, management expressed satisfaction with profitability improvement and positive cash generation.
Read more →TCMDTactile Medical Announces CEO Transition and Preliminary First Quarter 2024 Revenue CEO Dan Reuvers to retire; Healthcare veteran and board director Sheri Dodd appointed as Chief Executive Officer Preliminary, unaudited
Tactile Medical has announced the retirement of CEO Dan Reuvers, effective June 30, 2024, with board member Sheri Dodd appointed as his successor starting July 1, 2024. Dodd's extensive background in chronic care and leadership roles in major medical companies, including Medtronic, is anticipated to benefit the firm. The company also reported preliminary first quarter revenues of approximately $61 million, a growth from the $58.8 million reported in the same quarter of the previous year. Reuvers will assist Dodd as an advisor during the transition period until March 31, 2025.
Read more →TCMDTACTILE SYSTEMS TECHNOLOGY, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS; INTRODUCES FULL YEAR 2024 OUTLOOK Full Year Revenue Increased 11% Year-Over-Year; Full Year Net Income Increased 260%; Full Ye
Tactile Systems Technology, Inc. reported impressive financial results for the fourth quarter and full year 2023, showcasing a year-over-year revenue growth of 11% and a substantial increase in net income by 260%. The company's strategic focus on restoring lymphedema therapies and introducing new products has also contributed to their financial success. Looking ahead, Tactile Medical anticipates continued growth with projected revenue for 2024 between $300 million to $305 million. Overall, the results reflect strong operational performance and a robust balance sheet.
Read more →TCMDTACTILE SYSTEMS TECHNOLOGY, INC. REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS; UPDATES FULL YEAR 2023
Tactile Systems Technology, Inc. (TCMD) reported third-quarter 2023 financial results, showing a 6.6% increase in total revenue to $69.6 million. The growth was largely driven by a 15.3% rise in lymphedema product sales. The company recorded net income of $22.3 million, a notable recovery from a loss in the same quarter of the previous year. Though the overall performance was strong, there was a significant drop in airway clearance product sales, which raises some concerns.
Read more →TCMDTactile Medical Appoints Vindell Washington, M.D. to Board of Directors MINNEAPOLIS
Tactile Medical has appointed Dr. Vindell Washington, M.D. to its Board of Directors, effective October 2, 2023. Dr. Washington, recognized for his contributions to healthcare, will be a valuable asset with his extensive experience in medicine and health technology. His past roles include Chief Clinical Officer at Verily and executive positions in various healthcare organizations. This appointment aims to strengthen Tactile Medical's clinical strategy and enhance its mission in providing therapies for chronic disorders.
Read more →TCMDTACTILE SYSTEMS TECHNOLOGY, INC. REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS; UPDATES FULL YEAR 2023
Tactile Systems Technology, Inc. reported strong financial results for the second quarter of 2023, highlighting a revenue growth of 15% year-over-year. The company showed improvements in profitability, with operating income shifting from a loss to a gain. Despite these positive developments, Tactile Medical acknowledged a slight decrease in gross margin. Moving forward, the company updated its guidance for full-year 2023 revenue, projecting an increase driven by solid performance in their lymphedema product line.
Read more →TCMDTactile Medical Appoints Sherri Ferstler as Senior Vice President of Sales MINNEAPOLIS
Tactile Medical has appointed Sherri Ferstler as the new Senior Vice President of Sales, effective July 31, 2023. She succeeds Eric Pauls, who is resigning from the company. Ferstler brings extensive experience, having spent over 25 years in the healthcare industry, including significant roles at Johnson & Johnson Vision. Her leadership background in sales is anticipated to enhance the company's performance and growth capabilities.
Read more →TCMDTACTILE SYSTEMS TECHNOLOGY, INC. REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS; RAISES FULL YEAR 2023 OUTLOOK First Quarter Revenue Increased 23% Year-Over-Year MINNEAPOLIS, MN
Tactile Systems Technology, Inc. reported its first quarter 2023 financial results, highlighting a 23% increase in revenue year-over-year, totaling $58.8 million. The company improved its operating margins and reduced operating losses significantly from the previous year. Tactile Medical raised its full-year revenue guidance to a range of $271 to $275 million, reflecting confidence in continued growth despite caution regarding future macroeconomic conditions. Overall, the company's operational advancements and financial results position it positively for the remainder of the year.
Read more →TCMD▲ +5.1%on this news
Tactile Medical Appoints Elaine Birkemeyer as Chief Financial Officer MINNEAPOLIS, MN
Tactile Medical has appointed Elaine Birkemeyer as the new Chief Financial Officer, effective March 20, 2023. Birkemeyer succeeds Brent Moen, who is retiring, and brings over 25 years of experience in finance and business strategy from her previous roles at Fortune 500 companies, including UnitedHealth Group. The company is optimistic about its future, highlighting its focus on underserved chronic conditions and the potential for growth in its market.
Read more →About Tactile Systems Technology, Inc.
Headquarters1331 TYLER STREET NE STE 200, MINNEAPOLIS, MN, 55413
BIOPHARMAWATCH ELITE PLUS
Trade the next TCMD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime